false 0001979005 0001979005 2025-01-13 2025-01-13 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2025-01-13 2025-01-13 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2025-01-13 2025-01-13 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2025-01-13 2025-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

January 13, 2025

Date of Report (Date of earliest event reported)

 

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-41880   N/A
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (I.R.S. Employer
Identification No.)

 

10 East 53rd Street, Suite 3001

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

86-13758131392

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share   AFJK   The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share   AFJKR   The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right   AFJKU   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

Extension of the Termination Date

 

An aggregate of $227,700 (the “Extension Payment”) has been deposited into the trust account of Aimei Health Technology Co., Ltd (the “Company”) for its public shareholders, representing $0.033 per public share, which enables the Company to further extend the period of time it has to consummate its initial business combination by one month (the “Extension”) from January 6, 2025 to February 6, 2025 (the “Termination Date”). The Extension is the second of up to 12 extensions permitted under the Amended and Restated Articles of Association of the Company currently in effect.

 

Promissory Note

 

In connection with the Extension, the Company issued, on January 13, 2025, an unsecured promissory note in the total principal amount of $227,700 (the “Promissory Note”) to Aimei Health Ltd, a Cayman Islands exempted company (the “Sponsor”) and United Hydrogen Group Inc., an exempted company with limited liability incorporated in the Cayman Islands (“United Hydrogen,” and together with the Sponsor, the “Payees”). The amount was equally divided between the Payees, with each contributing $113,850, to fund the Extension Payment. The Promissory Note does not bear interest and the principal thereunder becomes due and payable upon the date on which the Company consummates a business combination with United Hydrogen (the “Business Combination”). The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company, at a price of $10.00 per unit, each consisting of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company, immediately prior to the consummation of the Business Combination, by providing the Company with written notices of their intention to convert the Promissory Note at least two business days prior to the closing of the Business Combination.

 

The foregoing description of the Promissory Note is not complete and is qualified in its entirety by reference to the text of such document, which is filed as Exhibit 10.1 hereto and which is incorporated herein by reference.

 

Item 9.01 Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Promissory Note, dated January 13, 2025, by and among Aimei Health Technology Co., Ltd, Aimei Health Ltd, and United Hydrogen Group Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 14, 2025

 

  Aimei Health Technology Co., Ltd
     
  By: /s/ Junheng Xie
  Name: Junheng Xie
  Title: Chief Executive Officer and Director
    (Principal Executive Officer)

 

 

 

 

Exhibit 10.1

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: US$227,700

Dated: January 13, 2025

 

FOR VALUE RECEIVED, Aimei Health Technology Co., Ltd (the “Maker” or the “Company”) promises to pay to the order of Aimei Investment Ltd and United Hydrogen Group Inc., or their registered assignees or successors in interest (collectively, the “Payees”), the principal sum of Two Hundred and Twenty-Seven Thousand and Seven Hundred dollars (US$227,700), to be shared equally between the Payees (US$113,850 each), on the terms and conditions described below. All payments on this Note shall be made by wire transfer of immediately available funds to such account as the Payees may from time to time designate by written notices in accordance with the provisions of this note (the “Note”).

 

1. Principal. The principal balance of this Note shall be payable by the Maker or successor entity after the Business Combination (as defined below) to the Payees upon the date on which the Maker consummates a business combination or merger with a qualified target company (as described in its Prospectus (as defined below)) (a “Business Combination”) (such date, the “Maturity Date”). The principal balance may be prepaid at any time prior to the Maturity Date without penalty. Under no circumstances shall any individual, including but not limited to any officer, director, employee or stockholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

 

2. Conversion Rights. The Payees have the right, but not the obligation, to convert this Note, in whole or in part, into private units (the “Units”) of the Maker, each consisting of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share, or into securities of the successor entity or entity surviving or resulting from the Business Combination (the “Successor Entity Securities”), upon the consummation of a Business Combination, as described in the Prospectus of the Maker (File Number 333-272230) (the “Prospectus”), by providing the Maker with written notices of their intention to convert this Note at least two business days prior to the closing of a Business Combination. The number of Units or Successor Entity Securities to be received by the Payees in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount payable to such Payees by (y) $10.00.

 

  (a) Fractional Units. No fractional Units will be issued upon conversion of this Note. In lieu of any fractional Units to which Payees would otherwise be entitled, the Maker will pay to Payees in cash the amount of the unconverted principal balance of this Note that would otherwise be converted into such fractional Units.

 

  (b) Effect of Conversion. If the Maker timely receives notices of the Payees’ intention to convert this Note at least two business days prior to the closing of a Business Combination, this Note shall be deemed to be converted on such closing date. At its expense, the Maker will, upon receipt of such conversion notices, as soon as practicable after consummation of a Business Combination, issue and deliver to Payees, at Payee’s address as requested by Payees in their conversion notices, a certificate or certificates for the number of Units or Successor Entity Securities to which Payees are entitled upon such conversion (bearing such legends as are customary pursuant to applicable state and federal securities laws), including a check payable to Payees for any cash amounts payable as a result of any fractional Units as described herein.

 

 
 

 

3. Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

4. Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including but not limited to reasonable attorney’s and auditor’s fees and expenses, then to the payment in full of any late charges, and finally to the reduction of the unpaid principal balance of this Note.

 

5. Events of Default. The following shall constitute an event of default (each, an “Event of Default”):

 

  (a) Failure to Make Required Payments. Failure by the Maker to pay the principal amount due pursuant to this Note more than 5 business days of the Maturity Date.

 

  (b) Voluntary Bankruptcy, etc. The commencement by the Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of the Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of the Maker generally to pay its debts as such debts become due, or the taking of corporate action by the Maker in furtherance of any of the foregoing.

 

  (c) Involuntary Bankruptcy, etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of the Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of the Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

 

  (d) Breach of Other Obligations. The Maker fails to perform or comply with any one or more of its obligations under this Note.

 

  (e) Unlawfulness and Invalidity. It is or becomes unlawful for the Maker to perform any of its obligations under this Note, or any obligations of the Maker under this Note are not or cease to be legal, valid, binding or enforceable.

 

6. Remedies.

 

  (a) Upon the occurrence of an Event of Default specified in Section 5(a) and 5(d) hereof, the Payees, acting jointly or individually, may, by written notices to the Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notices of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in the documents evidencing the same to the contrary.

 

  (b) Upon the occurrence of an Event of Default specified in Sections 5(b), 5(c), and 5(e) hereof, the unpaid principal balance of this Note, and all other sums payable with regard to this Note hereunder, shall automatically and immediately become due and payable, in all cases without any action on the part of the Payees.

 

7. Taxes. The Maker will pay all amounts due hereunder free and clear of and without reduction for any taxes, levies, imposts, deductions, withholding or charges imposed or levied by any governmental authority or any political subdivision or taxing authority thereof with respect thereto (“Taxes”). The Maker will pay on behalf of the Payees all such Taxes so imposed or levied and any additional amounts as may be necessary so that the net payment of principal and any interest on this Note received by the Payees after payment of all such Taxes shall be not less than the full amount provided hereunder.

 

 
 

 

8. Waivers. The Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by the Payees under the terms of this Note, and all benefits that might accrue to the Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and the Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by the Payees. The Payees hereby waive any and all right, title, interest, or claim of any kind (“Claim”) in or to the funds held in the trust account established in connection with the Maker’s IPO, including any interest earned thereon. The Payee agrees not to seek recourse, reimbursement, payment, or satisfaction of any Claim against the trust account or any distribution therefrom, whether in connection with this Note or otherwise

 

9. Unconditional Liability. The Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by the Payees, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by the Payees with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to the Maker or affecting the Maker’s liability hereunder. For the purpose of this Note, “business day” shall mean a day (other than a Saturday, Sunday or public holiday) on which banks are open in China and New York for general banking business.

 

10. Notices. All notices, statements or other documents which are required or contemplated by this Note shall be made in writing and delivered: (i) personally or sent by first class registered or certified mail, overnight courier service to the address most recently provided in writing to such party or such other address as may be designated in writing by such party,, or (ii) by email, to the email address most recently provided to such party or such other email address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on (a) the day of delivery, if delivered personally, (b) only if the receipt is acknowledged, the day after such receipt, if sent by email, (c) the business day after delivery to an overnight courier service, if sent by an overnight courier service, or (d) 5 days after mailing if sent by first class registered or certified mail.

 

11. Construction. This Note shall be construed and enforced in accordance with the laws of New York, without regard to conflict of law provisions thereof.

 

12. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. The Payees hereby waive any and all right, title, interest or claim of any kind (“Claim”) in or to any amounts contained in the trust account deriving from the proceeds of the IPO conducted by the Maker and the proceeds of the sale of securities in a private placement (if any) prior to the effectiveness of the IPO, as described in greater detail in the Prospectus filed with the Securities and Exchange Commission in connection with the IPO (the “Trust Account Funds”), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim from the Trust Account Funds or any distribution therefrom for any reason whatsoever. If Maker does not consummate the Business Combination, this Note shall be repaid only from amounts other than Trust Account Funds, if any.

 

13. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payees.

 

14. Assignment. This Note shall be binding upon the Maker and its successors and assigns and is for the benefit of the Payees and their respective successors and assigns, except that the Maker may not assign or otherwise transfer its rights or obligations under this Note. Each Payee may, at any time without the consent of or notice to the Maker, assign to one or more entities all or a portion of its rights under this Note. Any such assignment by one Payee shall not affect the rights or obligations of the other Payee or the Maker under this Note, except that the assignee(s) shall assume the rights and obligations of the assigning Payee with respect to the assigned portion.

 

[Signature Page Follows]

 

 
 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

MAKER:

 

Aimei Health Technology Co., Ltd

 

By: /s/ Junheng Xie  
Name: Junheng Xie  
Title: Chief Executive Officer and Director  

 

[Signature Page to the Promissory Note]

 

 

 

v3.24.4
Cover
Jan. 13, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2025
Entity File Number 001-41880
Entity Registrant Name AIMEI HEALTH TECHNOLOGY CO., LTD
Entity Central Index Key 0001979005
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 10 East 53rd Street
Entity Address, Address Line Two Suite 3001
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code 86
Local Phone Number 13758131392
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Ordinary Shares, par value $0.0001 per share  
Title of 12(b) Security Ordinary Shares, par value $0.0001 per share
Trading Symbol AFJK
Security Exchange Name NASDAQ
Rights, exchangeable into one-fifth of one Ordinary Share  
Title of 12(b) Security Rights, exchangeable into one-fifth of one Ordinary Share
Trading Symbol AFJKR
Security Exchange Name NASDAQ
Units, each consisting of one Ordinary Share and one Right  
Title of 12(b) Security Units, each consisting of one Ordinary Share and one Right
Trading Symbol AFJKU
Security Exchange Name NASDAQ

Aimei Health Technology (NASDAQ:AFJKU)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Aimei Health Technology 차트를 더 보려면 여기를 클릭.
Aimei Health Technology (NASDAQ:AFJKU)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Aimei Health Technology 차트를 더 보려면 여기를 클릭.